| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Sign In to gain access to subscriptions and/or personal tools.
|
|
|
|||||||
Sign In to gain access to subscriptions and/or personal tools. |
|||||||||
DRUG INTERACTIONS |
From the University of Washington, Departments of Pharmacy (Dr. Hebert, Dr. Park) and Medicine (Dr. Larson), Seattle, Washington, and Fujisawa Research Institute of America, Evanston, Illinois (Dr. Chen, Dr. Akhtar).
Tacrolimus is an immunosuppressant approved for the prevention of rejection following transplantation and is a substrate for CYP3A and P-glycoprotein. A pharmacokinetic interaction between St. John's wort (antidepressant herbal product and inducer of CYP3A and P-glycoprotein) and tacrolimus was evaluated in 10 healthy volunteers. The pharmacokinetics of tacrolimus were obtained from serial blood samples collected following single oral doses (0.1 mg/kg) prior to and during an 18-day concomitant St. John's wort dosing phase (300 mg orally three times daily). Coadministration of St. John's wort significantly decreased tacrolimus AUC (306.9 µg•h/L ± 175.8 µg•h/L vs. 198.7 µg•h/L ± 139.6 µg•h/L; p = 0.004) and increased apparent oral clearance (349.0 mL/h/kg ± 126.0 mL/h/kg vs. 586.4 mL/h/kg ± 274.9 mL/h/kg; p = 0.01) and apparent oral volume of distribution at steady state (11.5 L/kg ± 4.3 L/kg vs. 17.6 L/kg ± 9.6 L/kg; p = 0.04). St. John's wort appears to induce tacrolimus metabolism, most likely through induction of CYP3A and P-glycoprotein.
Key Words: St. John's wort • tacrolimus • organ transplantation • depression
Address for reprints: Mary F. Hebert, PharmD, University of Washington, Department of Pharmacy, H-375 Health Sciences Center, Box 357630, Seattle, WA 98195-7630.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Marchetti, R. Mazzanti, J. H. Beijnen, and J. H. M. Schellens Concise Review: Clinical Relevance of Drug Drug and Herb Drug Interactions Mediated by the ABC Transporter ABCB1 (MDR1, P-glycoprotein) Oncologist, August 1, 2007; 12(8): 927 - 941. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Uchida, H. Yamada, X. D. Li, S. Maruyama, Y. Ohmori, T. Oki, H. Watanabe, K. Umegaki, K. Ohashi, and S. Yamada Effects of ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers. J. Clin. Pharmacol., November 1, 2006; 46(11): 1290 - 1298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M Beringer and R. L Slaughter Transporters and Their Impact on Drug Disposition Ann. Pharmacother., June 1, 2005; 39(6): 1097 - 1108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K N Woodward The potential impact of the use of homeopathic and herbal remedies on monitoring the safety of prescription products Human and Experimental Toxicology, May 1, 2005; 24(5): 219 - 233. [Abstract] [PDF]
|
|
|
|
 |
|
 E. Mills, V. M Montori, P. Wu, K. Gallicano, M. Clarke, and G. Guyatt Interaction of St John's wort with conventional drugs: systematic review of clinical trials BMJ, July 3, 2004; 329(7456): 27 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sparreboom, M. C. Cox, M. R. Acharya, and W. D. Figg Herbal Remedies in the United States: Potential Adverse Interactions With Anticancer Agents J. Clin. Oncol., June 15, 2004; 22(12): 2489 - 2503. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
